More than 32% was wiped off the market value of antibody drug conjugate (ADC) specialist ImmunoGen (Nasdaq: IMGN) on Wednesday.
The US biotech company announced that the Food and Drug Administration (FDA) had asked that a new Phase III trial be conducted on mirvetuximab soravtansine in patients with high folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer, as part of a Type C meeting held this week.
"Our meeting with the FDA enabled us to clarify a regulatory path forward"Even before this announcement, ImmunoGen was reviewing its operations with the aim of extending the company’s cash resources. Mirvetuximab soravtansine is its lead product.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze